Wambui G Gathirua-Mwangi1, Patrick O Monahan2,3, Mwangi J Murage1, Jianjun Zhang4,5. 1. Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, 1050 Wishard Boulevard, RG5118, Indianapolis, IN, 46202, USA. 2. Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA. 3. Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA. 4. Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, 1050 Wishard Boulevard, RG5118, Indianapolis, IN, 46202, USA. jz21@iu.edu. 5. Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA. jz21@iu.edu.
Abstract
PURPOSE: Although metabolic syndrome incidence has substantially increased during the last few decades, it largely remains unclear whether this metabolic disorder is associated with total cancer mortality. The present study was carried out to investigate this important question. METHODS: A total of 687 cancer deaths were identified from 14,916 participants in the third National Health and Nutrition Examination Survey by linking them to the National Death Index database through December 31, 2006. Cox proportional hazards regression was performed to calculate hazard ratios (HR) and 95% confidence intervals (CI) for total cancer mortality in relation to metabolic syndrome and its individual components. RESULTS: After adjustment for confounders, a diagnosis of metabolic syndrome was associated with 33% elevated total cancer mortality. Compared with individuals without metabolic syndrome, those with 3, 4 and 5 abnormal components had HRs (95% CIs) of 1.28 (1.03-1.59), 1.24 (0.96-1.60), and 1.87 (1.34-2.63), respectively (p-trend = 0.0003). Systolic blood pressure and serum glucose were associated with an increased risk of death from total cancer [HR (95% CI) for highest vs. lowest quartiles: 1.67 (1.19-2.33), p-trend = 0.002 and 1.34 (1.04-1.74), p-trend = 0.003, respectively]. Overall null results were obtained for lung cancer mortality. The effects of metabolic syndrome and its components on non-lung cancer mortality were generally similar to, but somewhat larger than, those for total cancer mortality. CONCLUSION: Our study is among the first to reveal that metabolic syndrome is associated with increased total cancer mortality.
PURPOSE: Although metabolic syndrome incidence has substantially increased during the last few decades, it largely remains unclear whether this metabolic disorder is associated with total cancer mortality. The present study was carried out to investigate this important question. METHODS: A total of 687 cancer deaths were identified from 14,916 participants in the third National Health and Nutrition Examination Survey by linking them to the National Death Index database through December 31, 2006. Cox proportional hazards regression was performed to calculate hazard ratios (HR) and 95% confidence intervals (CI) for total cancer mortality in relation to metabolic syndrome and its individual components. RESULTS: After adjustment for confounders, a diagnosis of metabolic syndrome was associated with 33% elevated total cancer mortality. Compared with individuals without metabolic syndrome, those with 3, 4 and 5 abnormal components had HRs (95% CIs) of 1.28 (1.03-1.59), 1.24 (0.96-1.60), and 1.87 (1.34-2.63), respectively (p-trend = 0.0003). Systolic blood pressure and serum glucose were associated with an increased risk of death from total cancer [HR (95% CI) for highest vs. lowest quartiles: 1.67 (1.19-2.33), p-trend = 0.002 and 1.34 (1.04-1.74), p-trend = 0.003, respectively]. Overall null results were obtained for lung cancer mortality. The effects of metabolic syndrome and its components on non-lung cancer mortality were generally similar to, but somewhat larger than, those for total cancer mortality. CONCLUSION: Our study is among the first to reveal that metabolic syndrome is associated with increased total cancer mortality.
Entities:
Keywords:
Epidemiology; Lung cancer mortality; Metabolic syndrome; Non-lung cancer mortality, cohort study; Obesity; Total cancer mortality
Authors: Laura A Colangelo; Susan M Gapstur; Peter H Gann; Alan R Dyer; Kiang Liu Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-04 Impact factor: 4.254
Authors: Wendy Demark-Wahnefried; Elizabeth A Platz; Jennifer A Ligibel; Cindy K Blair; Kerry S Courneya; Jeffrey A Meyerhardt; Patricia A Ganz; Cheryl L Rock; Kathryn H Schmitz; Thomas Wadden; Errol J Philip; Bruce Wolfe; Susan M Gapstur; Rachel Ballard-Barbash; Anne McTiernan; Lori Minasian; Linda Nebeling; Pamela J Goodwin Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-13 Impact factor: 4.254
Authors: Luigino Dal Maso; Antonella Zucchetto; Renato Talamini; Diego Serraino; Carmen F Stocco; Marina Vercelli; Fabio Falcini; Silvia Franceschi Journal: Int J Cancer Date: 2008-11-01 Impact factor: 7.396
Authors: Wambui G Gathirua-Mwangi; Yiqing Song; Patrick O Monahan; Victoria L Champion; Terrell W Zollinger Journal: Int J Cancer Date: 2018-03-14 Impact factor: 7.396
Authors: Grzegorz Józef Nowicki; Barbara Ślusarska; Katarzyna Naylor; Andrzej Prystupa; Ewa Rudnicka-Drożak; Ulyana Halyuk; Petro Pokotylo Journal: Diabetes Metab Syndr Obes Date: 2021-05-06 Impact factor: 3.168
Authors: Daniel T Dibaba; Suzanne E Judd; Susan C Gilchrist; Mary Cushman; Maria Pisu; Monika Safford; Tomi Akinyemiju Journal: Metabolism Date: 2019-02-23 Impact factor: 8.694
Authors: Yuan Yuan; Kathy Pan; Joanne Mortimer; Rowan T Chlebowski; Juhua Luo; Jessica E Yan; Susan E Yost; Candyce H Kroenke; Lucile Adams-Campbell; Rami Nassir; Yangbo Sun; Aladdin H Shadyab; Mara Z Vitolins; Nazmus Saquib; Robert A Wild; JoAnn E Manson; Rebecca A Nelson Journal: Cancer Date: 2021-01-21 Impact factor: 6.921